SNAP23 and neoplasm: Finally, a catalytic light chain of botulism toxin E protease engineered to cleave SNAP23 suppresses in vivo tumorigenesis by KRAS-driven tumor cells, indicating that vesicular transporters may provide a therapeutic opportunity in KRAS-dependent malignancies.